Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerome Lewis Avorn, M.D.

Co-Author

This page shows the publications co-authored by Jerome Avorn and Daniel Solomon.
Connection Strength

10.411
  1. Osteoporosis improvement: a large-scale randomized controlled trial of patient and primary care physician education. J Bone Miner Res. 2007 Nov; 22(11):1808-15.
    View in: PubMed
    Score: 0.394
  2. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf. 2005 Apr; 14(4):219-26.
    View in: PubMed
    Score: 0.330
  3. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc. 2005 Feb; 80(2):194-202.
    View in: PubMed
    Score: 0.326
  4. Osteoporosis action: design of the healthy bones project trial. Contemp Clin Trials. 2005 Feb; 26(1):78-94.
    View in: PubMed
    Score: 0.326
  5. Coxibs, science, and the public trust. Arch Intern Med. 2005 Jan 24; 165(2):158-60.
    View in: PubMed
    Score: 0.325
  6. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug; 44(2):140-5.
    View in: PubMed
    Score: 0.313
  7. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.309
  8. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.301
  9. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003 Oct 01; 115(5):398-400.
    View in: PubMed
    Score: 0.297
  10. Trends in knee magnetic resonance imaging. Med Care. 2003 May; 41(5):687-92.
    View in: PubMed
    Score: 0.289
  11. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol. 2003 Apr; 30(4):792-8.
    View in: PubMed
    Score: 0.287
  12. Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr Opin Rheumatol. 2003 Mar; 15(2):122-6.
    View in: PubMed
    Score: 0.285
  13. Do gastroprotective drugs prevent NSAID toxicity? J Rheumatol. 2003 Jan; 30(1):203; author reply 203-4.
    View in: PubMed
    Score: 0.282
  14. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002 Jul 06; 360(9326):90.
    View in: PubMed
    Score: 0.273
  15. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002 May 27; 162(10):1099-104.
    View in: PubMed
    Score: 0.271
  16. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol. 2001 Oct; 38(4):969-76.
    View in: PubMed
    Score: 0.259
  17. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001 Aug 13-27; 161(15):1897-902.
    View in: PubMed
    Score: 0.256
  18. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000 Jul 18; 133(2):128-35.
    View in: PubMed
    Score: 0.238
  19. Nonoccupational risk factors for carpal tunnel syndrome. J Gen Intern Med. 1999 May; 14(5):310-4.
    View in: PubMed
    Score: 0.219
  20. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.140
  21. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013 Jan; 24(1):237-44.
    View in: PubMed
    Score: 0.136
  22. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 2012 Mar 26; 172(6):477-83.
    View in: PubMed
    Score: 0.133
  23. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012; 7(2):e31894.
    View in: PubMed
    Score: 0.133
  24. Correlations of nursing home characteristics with prescription of osteoporosis medications. Bone. 2011 May 01; 48(5):1164-8.
    View in: PubMed
    Score: 0.124
  25. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.114
  26. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. 2009 Dec; 20(12):2127-34.
    View in: PubMed
    Score: 0.110
  27. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial. Osteoporos Int. 2010 Jan; 21(1):137-44.
    View in: PubMed
    Score: 0.110
  28. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.108
  29. Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc. 2009 Feb; 57(2):327-34.
    View in: PubMed
    Score: 0.108
  30. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.
    View in: PubMed
    Score: 0.104
  31. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.104
  32. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.
    View in: PubMed
    Score: 0.103
  33. Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch Intern Med. 2008 May 26; 168(10):1111-5.
    View in: PubMed
    Score: 0.103
  34. High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania. Int Q Community Health Educ. 2008-2009; 29(3):223-40.
    View in: PubMed
    Score: 0.100
  35. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers. Med Care. 2007 Oct; 45(10 Supl 2):S38-43.
    View in: PubMed
    Score: 0.098
  36. The medical license number accurately identifies the prescribing physician in a large pharmacy claims database. Med Care. 2007 Sep; 45(9):907-10.
    View in: PubMed
    Score: 0.097
  37. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008 May; 67(5):609-13.
    View in: PubMed
    Score: 0.097
  38. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.
    View in: PubMed
    Score: 0.097
  39. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
    View in: PubMed
    Score: 0.096
  40. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007 Aug 01; 166(3):348-54.
    View in: PubMed
    Score: 0.095
  41. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007 Apr 23; 167(8):847-52.
    View in: PubMed
    Score: 0.095
  42. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Dec; 54(12):3790-8.
    View in: PubMed
    Score: 0.093
  43. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care. 2006 Jul; 44(7):658-63.
    View in: PubMed
    Score: 0.090
  44. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec; 65(12):1608-12.
    View in: PubMed
    Score: 0.090
  45. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006 Jul; 1(4):796-801.
    View in: PubMed
    Score: 0.089
  46. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.089
  47. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006; 8(3):R57.
    View in: PubMed
    Score: 0.088
  48. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum. 2006 Feb 15; 55(1):35-41.
    View in: PubMed
    Score: 0.088
  49. A randomized controlled trial of mailed osteoporosis education to older adults. Osteoporos Int. 2006; 17(5):760-7.
    View in: PubMed
    Score: 0.087
  50. Lipid levels and bone mineral density. Am J Med. 2005 Dec; 118(12):1414.
    View in: PubMed
    Score: 0.086
  51. Compliance with osteoporosis medications. Arch Intern Med. 2005 Nov 14; 165(20):2414-9.
    View in: PubMed
    Score: 0.086
  52. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005 Aug; 46(2):225-32.
    View in: PubMed
    Score: 0.084
  53. Older adults' knowledge and beliefs about osteoporosis: results of semistructured interviews used for the development of educational materials. J Rheumatol. 2005 Apr; 32(4):673-7.
    View in: PubMed
    Score: 0.082
  54. Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum. 2005 Feb 15; 53(1):61-6.
    View in: PubMed
    Score: 0.082
  55. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.081
  56. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.081
  57. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004 Nov 18; 351(21):2187-94.
    View in: PubMed
    Score: 0.080
  58. Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med. 2004 Aug 9-23; 164(15):1641-9.
    View in: PubMed
    Score: 0.079
  59. Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. J Gen Intern Med. 2004 Jul; 19(7):783-90.
    View in: PubMed
    Score: 0.078
  60. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.078
  61. Which patients with knee problems are likely to benefit from nonarthroplasty surgery? Development of a clinical prediction rule. Arch Intern Med. 2004 Mar 08; 164(5):509-13.
    View in: PubMed
    Score: 0.077
  62. Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med. 2003 Nov 24; 163(21):2585-9.
    View in: PubMed
    Score: 0.075
  63. Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris. Am J Cardiol. 2003 Aug 15; 92(4):363-7.
    View in: PubMed
    Score: 0.074
  64. Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum. 2003 Aug; 48(8):2207-13.
    View in: PubMed
    Score: 0.073
  65. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):67-70.
    View in: PubMed
    Score: 0.071
  66. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol. 2002 Feb; 55(2):121-8.
    View in: PubMed
    Score: 0.066
  67. Patterns of drug use in rheumatoid arthritis. J Rheumatol. 2000 Jul; 27(7):1648-55.
    View in: PubMed
    Score: 0.059
  68. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000 Jun 28; 283(24):3211-6.
    View in: PubMed
    Score: 0.059
  69. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012 Oct 30; 60(18):1817-24.
    View in: PubMed
    Score: 0.035
  70. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health. 2011 Jun; 14(4):513-20.
    View in: PubMed
    Score: 0.031
  71. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov; 29(11):1995-2001.
    View in: PubMed
    Score: 0.030
  72. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Med Care. 2009 Sep; 47(9):1031-5.
    View in: PubMed
    Score: 0.028
  73. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. J Gen Intern Med. 2009 May; 24(5):570-8.
    View in: PubMed
    Score: 0.027
  74. Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. Kidney Int. 2007 May; 71(9):938-45.
    View in: PubMed
    Score: 0.024
  75. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens. 2007 Mar; 25(3):689-97.
    View in: PubMed
    Score: 0.024
  76. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.023
  77. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 Dec 01; 353(22):2335-41.
    View in: PubMed
    Score: 0.022
  78. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.